Stryker is trading 10.95% down at $279.02 after its October 29 earnings report and the company’s lowered 2026 outlook. - Adjusted EPS of $3.52 and revenue of $6.5 billion missed analyst expectations. - Stryker lowered its 2026 organic sales growth and adjusted EPS outlook. - Management cited softer hip and knee trends, lingering supply constraints, and capital-equipment execution risks; no pre-market volume figure was provided.